



RECEIVED

MAY 24 2002

TECH CENTER 1600/2900

**I Claim:**

1. Cancelled.

2. Cancelled.

3. Cancelled.

4. Cancelled.

5. Cancelled.

6. Cancelled.

7. Cancelled.

8. A method for the treatment of retina or optic nerve head neuropathy which comprises administering to a mammal a composition comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.

9. (Amended) A method according to Claim 8, wherein the neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), [idebenone], ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol..

10. A method according to Claim 9, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

11. A method according to Claim 8, wherein the composition is an oral formulation.

12. A method according to Claim 8, wherein the composition is a topical ophthalmic, or intraocular formulation.

COPY OF PAPERS  
ORIGINALLY FILED

13. A method according to Claim 10, wherein the composition is an oral formulation.

5 14. A method according to Claim 10, wherein the composition is a topical ophthalmic, or intraocular formulation.